Literature DB >> 26867023

Identification and Treatment of New Inflammatory Triggers for Complex Regional Pain Syndrome: Small Intestinal Bacterial Overgrowth and Obstructive Sleep Apnea.

Leonard B Weinstock1, Trisha L Myers, Arthur S Walters, Oscar A Schwartz, Jarred W Younger, Pradeep J Chopra, Anthony H Guarino.   

Abstract

Complex regional pain syndrome (CRPS) is evoked by conditions that may be associated with local and/or systemic inflammation. We present a case of long-standing CRPS in a patient with Ehlers-Danlos syndrome in which prolonged remission was attained by directing therapy toward concomitant small intestinal bacterial overgrowth, obstructive sleep apnea, and potential increased microglia activity. We theorize that cytokine production produced by small intestinal bacterial overgrowth and obstructive sleep apnea may act as stimuli for ongoing CRPS symptoms. CRPS may also benefit from the properties of low-dose naltrexone that blocks microglia Toll-like receptors and induces production of endorphins that regulate and reduce inflammation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26867023     DOI: 10.1213/XAA.0000000000000292

Source DB:  PubMed          Journal:  A A Case Rep        ISSN: 2325-7237


  3 in total

1.  Low-dose Naltrexone for the treatment of sarcoidosis.

Authors:  Leonard B Weinstock; Trisha L Myers; Anup Shetty
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

2.  Risk of Postoperative Hyperalgesia in Adult Patients with Preoperative Poor Sleep Quality Undergoing Open-heart Valve Surgery.

Authors:  Zhe Zhang; Hongbai Wang; Yuefu Wang; Qipeng Luo; Su Yuan; Fuxia Yan
Journal:  J Pain Res       Date:  2020-10-13       Impact factor: 3.133

3.  Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment.

Authors:  Leonard B Weinstock; Jill B Brook; Trisha L Myers; Brent Goodman
Journal:  BMJ Case Rep       Date:  2018-01-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.